Early Bird Discount for DIA EuroMeeting Ends on February 11
The DIA has announced that its early registration fee reduction for next month's EuroMeeting will end on Tuesday February 11.
The DIA has announced that its early registration fee reduction for next month’s EuroMeeting will end on Tuesday February 11. The standard member’s registration for the meeting will rise from 1700 euros to 1850 euros after February 11, according to the organizers.
Also, a new co-chair has been appointed for the congress: Christa Wirthumer-Hoche, who recently became Head of the Austrian Medicines Agency.
The conference will take place in Vienna, Austria, from 25 to 27 March 2014. It is likely to attract over 3,000 delegates from more than 50 countries. It brings together professionals from the biopharmaceutical industry, contract research and service organizations, academic research centers, regulatory agencies and health ministries, as well as delegates from patient organizations.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
